{"id":2568,"date":"2009-11-12T05:07:12","date_gmt":"2009-11-12T10:07:12","guid":{"rendered":"http:\/\/asweetlife.org\/?p=2568"},"modified":"2015-12-28T08:12:09","modified_gmt":"2015-12-28T13:12:09","slug":"novo-nordisk-progress-made-in-oral-insulin-development","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=2568","title":{"rendered":"Novo Nordisk: Progress Made in Oral Insulin Development"},"content":{"rendered":"<p><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2009\/11\/Novo-Nordisk-Logo.png\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-29495 lazyload\" title=\"Novo Nordisk Logo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2009\/11\/Novo-Nordisk-Logo.png\" alt=\"\" width=\"215\" height=\"160\" \/><\/a>Lars Sorensen, Novo&#8217;s chief executive, speaking at the <a href=\"http:\/\/www.reuters.com\/article\/Health09\/idUSTRE5AA3R420091111\">Reuters<\/a> Health Summit, said the company could introduce a oral insulin tablet to the market within six years.<\/p>\n<p>A number of companies have already tried to develop inhaled insulin, including Pfizer Inc, whose product Exubera, was discontinued in 2007.\u00a0 This form of insulin has raised concerns that it could cause lung damage.<\/p>\n<p>The main challenge for scientists trying to develop insulin tablets is that insulin degrades quickly in the stomach, meaning only a very small amount reaches the bloodstream. Novo may have found a way around the problem.<\/p>\n<p>According to Sorensen, first product candidates are currently going into human clinical trials.<\/p>\n<p>The development of an oral insulin is part of a broader push by Novo Nordisk to develop next-generation diabetes treatments. The company is also working to develop the first tablet form of its protein-based injectable diabetes drug Victoza (competing with Eli Lilly&#8217;s and Amylin Pharmaceuticals Inc&#8217;s Byetta) which is yet to be approved in the US.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lars Sorensen, Novo&#8217;s chief executive, speaking at the Reuters Health Summit, said the company could introduce a oral insulin tablet to the market within six years.<br \/>\nA number of companies have already tried to develop inhaled insulin, including Pfizer Inc, whose product Exubera, was discontinued in 2007.  This form of insulin has raised concerns that it could cause lung damage.<\/p>\n","protected":false},"author":131,"featured_media":29495,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1441],"tags":[312,311],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novo Nordisk: Progress Made in Oral Insulin Development<\/title>\n<meta name=\"description\" content=\"Lars Sorensen, Novo&#039;s chief executive, speaking at the Reuters Health Summit, said the company could introduce a oral insulin tablet to the market within six years.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=2568\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=2568\",\"url\":\"https:\/\/asweetlife.org\/?p=2568\",\"name\":\"Novo Nordisk: Progress Made in Oral Insulin Development\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=2568#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=2568#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2009\/11\/Novo-Nordisk-Logo.png\",\"datePublished\":\"2009-11-12T10:07:12+00:00\",\"dateModified\":\"2015-12-28T13:12:09+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"Lars Sorensen, Novo's chief executive, speaking at the Reuters Health Summit, said the company could introduce a oral insulin tablet to the market within six years.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=2568#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=2568\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=2568#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2009\/11\/Novo-Nordisk-Logo.png\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2009\/11\/Novo-Nordisk-Logo.png\",\"width\":215,\"height\":160,\"caption\":\"Novo Nordisk Logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=2568#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk: Progress Made in Oral Insulin Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk: Progress Made in Oral Insulin Development","description":"Lars Sorensen, Novo's chief executive, speaking at the Reuters Health Summit, said the company could introduce a oral insulin tablet to the market within six years.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=2568","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=2568","url":"https:\/\/asweetlife.org\/?p=2568","name":"Novo Nordisk: Progress Made in Oral Insulin Development","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=2568#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=2568#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2009\/11\/Novo-Nordisk-Logo.png","datePublished":"2009-11-12T10:07:12+00:00","dateModified":"2015-12-28T13:12:09+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"Lars Sorensen, Novo's chief executive, speaking at the Reuters Health Summit, said the company could introduce a oral insulin tablet to the market within six years.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=2568#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=2568"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=2568#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2009\/11\/Novo-Nordisk-Logo.png","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2009\/11\/Novo-Nordisk-Logo.png","width":215,"height":160,"caption":"Novo Nordisk Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=2568#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk: Progress Made in Oral Insulin Development"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/2568"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2568"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/2568\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/29495"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}